AMED Stock Recent News

BATON ROUGE, La., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period and year ended December 31, 2024.

Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BATON ROUGE, La., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice and high-acuity care services, has recognized 47 employees with the prestigious Spirit of Excellence Awards, one of the company's highest honors.

President Trump has endorsed the passage of a tax credit for family caregivers. The tax credit would be given to caregivers who take care of a parent, family member, or a loved one.

UNH and AMED are now expected to identify new buyers for the divestment assets by March 2025.

Amedisys' expected merger with UnitedHealth Group's Optum brings optimism to investors. Yet, a dull macroeconomic condition adds to the worry.

UnitedHealth Group Inc (NYSE:UNH, ETR:UNH) and Amedisys (NASDAQ:AMED) have agreed to extend the deadline for their $3.3 billion merger, facing ongoing scrutiny from the US Department of Justice (DOJ). The companies announced in a regulatory filing that the merger deadline will now be extended to 10 days after a final court decision is issued or December 31, 2025, whichever comes first. This development follows a lawsuit filed over a month ago by the DOJ and attorneys general from Maryland, New Jersey, and New York to block the merger. Regulators argue that the deal would reduce competition in the home health services market, potentially harming patients, insurers, and nurses. The original deadline for the merger was set for today. Under a new waiver agreement, the companies have adjusted financial terms, including a regulatory break fee of $275 million, which could rise to $325 million if specific asset divestitures are not completed by May 1. Other modifications to the agreement inclu

Midnight Sun Mining Corp (TSX-V:MMA, OTCQB:MDNGF) director of marketing and communications Adrian O'Brien talked with Proactive about securing approval from Zambia's Mines Ministry for the renewal of the Kazhiba target license. He emphasized that the license is a cornerstone of the cooperative exploration plan with First Quantum Minerals (TSX:FM). Proactive: Exciting news about the company’s license renewal for your Kazhiba target. This is really the end of a long journey. Can you bring everyone up to date on where things stand? Adrian O'Brien: Certainly. We've just received approval from the Mines Ministry of Zambia for the renewal of the license covering our Kazhiba target. This is a crucial part of our cooperative exploration plan with First Quantum Minerals. We've been waiting for this approval for some time due to a clerical error last summer, which showed the license as rejected. Thankfully, the Zambian ministry was great, and the situation has been resolved. This renewal sets

UnitedHealth Group Inc (NYSE:UNH, ETR:UNH) and Amedisys (NASDAQ:AMED) have agreed to extend the deadline for their $3.3 billion merger, facing ongoing scrutiny from the US Department of Justice (DOJ). The companies announced in a regulatory filing that the merger deadline will now be extended to 10 days after a final court decision is issued or December 31, 2025, whichever comes first.

UnitedHealth Group (UNH) and Amedisys (AMED) agreed to extend the deadline to complete their $3.3 billion merger, after the U.S. Department of Justice moved to block it.